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Abstract
Vpx is a small virion-associated adaptor protein encoded by viruses of the HIV-2/SIVsm lineage of primate lentiviruses that
enables these viruses to transduce monocyte-derived cells. This probably reflects the ability of Vpx to overcome an as yet
uncharacterized block to an early event in the virus life cycle in these cells, but the underlying mechanism has remained
elusive. Using biochemical and proteomic approaches, we have found that Vpx protein of the pathogenic SIVmac 239 strain
associates with a ternary protein complex comprising DDB1 and VprBP subunits of Cullin 4–based E3 ubiquitin ligase, and
DDA1, which has been implicated in the regulation of E3 catalytic activity, and that Vpx participates in the Cullin 4 E3
complex comprising VprBP. We further demonstrate that the ability of SIVmac as well as HIV-2 Vpx to interact with VprBP
and its associated Cullin 4 complex is required for efficient reverse transcription of SIVmac RNA genome in primary
macrophages. Strikingly, macrophages in which VprBP levels are depleted by RNA interference resist SIVmac infection. Thus,
our observations reveal that Vpx interacts with both catalytic and regulatory components of the ubiquitin proteasome
system and demonstrate that these interactions are critical for Vpx ability to enable efficient SIVmac replication in primary
macrophages. Furthermore, they identify VprBP/DCAF1 substrate receptor for Cullin 4 E3 ubiquitin ligase and its associated
protein complex as immediate downstream effector of Vpx for this function. Together, our findings suggest a model in
which Vpx usurps VprBP-associated Cullin 4 ubiquitin ligase to enable efficient reverse transcription and thereby overcome
a block to lentivirus replication in monocyte-derived cells, and thus provide novel insights into the underlying molecular
mechanism.
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Introduction
Vpx accessory proteins are virulence factors encoded by viruses
of the HIV-2/SIVsm/SIVmac lineage of primate lentiviruses. vpx
gene disruption results in greatly reduced rates of virus replication
in monocyte-derived cells, such as differentiated macrophages, but
has no overt effect in primary T lymphocytes, as well as T and
monocytic cell lines [1,2,3]. Intact vpx gene is required for optimal
replication of these viruses in the infected host [4,5]. Thus, it is
thought that the role of Vpx in natural infection is to enable the
establishment of virus reservoirs in macrophages.
Vpx is recruited into viral particles through the interaction with
the p6 component of Gag [6,7], and thus is available to facilitate
an early event in the virus life cycle upon virion entry into the
target cell. Indeed, an early study revealed that Vpx is required for
efficient transport of preintegration complexes to the nuclei of
infected macrophages [3]. In more recent studies HIV-2 and
SIVsm Vpx proteins were found to promote accumulation of
reverse transcribed viral genomes upon infection of dendritic cells
(DCs) and this effect may reflect the ability of Vpx to overcome a
proteasome dependent mechanism that inhibits an as of yet
unidentified early event in the viral replication cycle [8]. How Vpx
intersects this ubiquitin-dependent proteasomal protein degrada-
tion mechanism is unclear.
Vpx is a paralogue of Vpr accessory factor encoded by all
known lineages of primate lentiviruses [9]. Although their amino
acid sequences are closely related, the two proteins have different
roles along the viral life cycle. For example, Vpr has the ability to
activate DNA damage checkpoint and thereby arrest cells in the
G2 phase of the cell cycle, while Vpx does not possess this function
(reviewed in [10]). Results from recent proteomic studies revealed
that lentiviral Vpr proteins associate with components of the
ubiquitin proteasome system (UPS), such as Vpr Binding Protein
(VprBP, GenBank NM014703) termed also DDB1 and CUL4-
associated factor 1 (DCAF1), damaged DNA-binding protein 1
(DDB1, GenBank U18299), DET1 and DDB1 associated 1
(DDA1, GenBank DQ090952) and Cullin 4 (GenBank
NM001008895, NM003588) ([11,12,13] reviewed in [14]). Cullin
4 is a scaffold protein that assembles a family of E3 ubiquitin ligase
complexes. DDB1 is an obligatory subunit of all Cullin 4 E3’s that
bridges the catalytic cores organized on the Cullin 4 scaffold to a
substrate-recruiting subunit, and VprBP/DCAF1 is a putative
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substrate adaptor for Cullin 4-based E3 ubiquitin ligases ([15]
reviewed in [16,17]). Evidence has been obtained showing that
these interactions provide Vpr with the ability to modulate
specifically the intrinsic catalytic activity of the Cullin 4 E3
containing VprBP and with a potential to influence the
recruitment of substrate proteins for ubiquitination by Cullin 4,
which in turn leads to the activation of DNA damage checkpoint
[13,18].
Since Vpx, similarly to Vpr, probably functions as an adaptor
protein, we have used a combination of biochemical and
proteomic methods to identify downstream effectors of Vpx
encoded by the pathogenic SIVmac 239 strain. Here we show that
SIVmac Vpx also binds DDA1-DDB1-VprBP complex, which
links Vpx to Cullin 4, thus extending the previous observation that
another SIV Vpx variant can bind VprBP [11]. Importantly, we
demonstrate that VprBP, and its interaction with Vpx, are
required for efficient macrophage transduction by SIVmac.
Surprisingly, in the absence of Vpx, the incoming RNA genome
is reverse transcribed very inefficiently. These findings indicate
that Vpx facilitates macrophage infection by acting prior to and/
or during reverse transcription, rather than by facilitating nuclear
transport of the fully reverse transcribed preintegration complex,
as has been thought previously ([3], reviewed in [10]). Together,
our findings identify the UPS system and the VprBP associated
protein complex as cellular machinery and immediate downstream
effector that Vpx uses to promote replication of cognate primate
lentiviruses in cells of monocyte/macrophage lineage, and provide
novel insights into the underlying mechanisms.
Results
Vpx binds DDA1, DDB1 and VprBP components of the
UPS
Two complementary strategies were used to identify cellular
proteins that are bound by SIVmac 239 Vpx. As one approach,
U937 monocytic cell populations were transduced with BABE-
puro retroviral vectors stably expressing Vpx tagged at its N-
terminus with a triple HA-FLAG-AU1 epitope tag (hfa-Vpx). The
population of positively transduced cells was then selected with
puromycin and expanded in spinner cultures for biochemical
experiments. Surprisingly, we observed that U937 cells that stably
expressed Vpx grew more slowly than the control U937
population transduced with an empty BABE-puro vector (data
not shown), suggesting that Vpx is toxic and/or cytostatic to these
cells. This in turn raised the possibility that chronic Vpx
expression could lead to selection of escape variants where Vpx
interaction with cellular proteins is not faithfully reproduced.
Therefore, as an additional approach hfa-Vpx was expressed
transiently in human embryonic kidney 293T (HEK 293T) cells by
calcium phosphate co-precipitation. Next, Vpx and its associated
proteins were purified from U937 and HEK 293T detergent
extracts by sequential immunoprecipitations with anti-HA- and
anti-FLAG- epitope antibodies, each followed by elution with the
respective peptide epitope.
The immunoprecipitates were proteolyzed without prior
separation of protein bands by SDS-PAGE and peptide mixtures
analyzed by multidimensional protein identification technology
(MudPIT, [19]). Interestingly, the most abundant cellular
polypeptides we found associated with Vpx both in U937 and
HEK 293T cells, but were absent from control purifications from
cells that did not express Vpx were DDA1, DDB1 and VprBP/
DCAF1 (see Table 1). Significantly, DDB1, an obligatory subunit
of all known Cullin 4 based E3 ubiquitin ligases [16], VprBP, a
known Vpr-binding cellular protein that has been recently shown
to bind DDB1 and postulated to function as a substrate receptor
for Cullin 4 E3 ubiquitin ligase [15,20] and DDA1, a DDB1-
binding protein that links to a negative regulator of Cullin4 E3
ubiquitin ligases [21], were thus identified as relatively abundant
Vpx-associated proteins. Notably, DDB1, VprBP and DDA1 were
recently shown to assemble a ternary complex that associates with
Vpr proteins of HIV-1 and SIVmac and mediates activation of
DNA damage checkpoint by these accessory factors [13]. Thus,
our observations suggested that Vpx and its Vpr paralog both act
through the DDA1-DDB1-VprBP complex, even though the two
proteins execute distinct functions.
To verify the data from MudPIT analyses, experiments were
performed to confirm that Vpx associates specifically with the
endogenous DDB1-VprBP-DDA1 complex. hfa-Vpx was transient-
ly expressed in HEK 293T cells. Then, hfa-Vpx and its associated
proteins were immunoprecipitated from detergent extracts pre-
pared from the transfected cells with anti-FLAG-affinity resin,
separated by SDS-PAGE and analyzed by western blotting with
Table 1. MudPIT identification of cellular proteins that
specifically associate with SIVmac Vpx in U937 monocytes and
HEK 293T cells.
Cell line: U937 HEK 293T
Epitope tagged subunit: SIVmac Vpx Mock SIVmac Vpx Mock
Vpx 17a: 32.7b 398; 76.0
Ubiquitous:
DDB1 19; 10.7 12; 6.6
VprBP 22; 11.2 33; 16.8
DDA1 8; 38.2 4; 26.5
(a)Spectral count, number of tandem mass spectrometry spectra matching
peptides from the indicated protein.
(b)Sequence coverage, percentage of protein sequence represented in peptides
identified by mass spectrometry.
doi:10.1371/journal.ppat.1000059.t001
Author Summary
Monocyte-derived tissue macrophages play crucial roles in
infection by primate lentiviruses. Human and simian
lentiviruses of the HIV-2 and SIVsm/mac lineages encode
a virion-bound virulence factor termed Vpx. Vpx is required
to establish infection specifically of monocyte-derived
cells, but the underlying molecular mechanism is unclear.
In this study we characterize how the replication of SIVmac
is blocked in the absence of Vpx and how Vpx overcomes
this block. We find that Vpx is required for efficient reverse
transcription of the incoming RNA genome, suggesting
that Vpx acts early following virion entry into the
macrophage, probably on events linked to virion uncoat-
ing and/or reverse transcription. We also identified a Vpx-
associated ternary protein complex that is the key
mediator of Vpx function specifically in macrophages. This
complex links Vpx to the cellular machinery that mediates
protein ubiquitination and degradation. Together, we
describe the immediate downstream effector, the molec-
ular machinery and a tentative mechanism that lentiviral
Vpx uses to enable reverse transcription in macrophages.
Our findings should lead to the conception of new
strategies to control macrophage infection by human
and simian lentiviruses.
Vpx Promotes Macrophage Infection via VprBP/DCAF1
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antibodies specific for VprBP, DDB1 and DDA1. As shown in
Figure 1A, VprBP, DDB1 and DDA1 were readily detected in
immune complexes isolated from hfa-Vpx expressing, but not from
control, HEK 293T cells. Thus these data confirm that Vpx
associates with DDB1, VprBP and DDA1 (compare lane 2 with 1).
The C-terminal region of Vpx mediates binding to DDA1-
DDB1-VprBP complex
The finding that Vpx associates with DDA1, VprBP and DDB1
was not entirely surprising because SIVmac Vpx amino acid
sequence is approximately 25% and 50% identical to those of
HIV-1 and SIVmac Vpr proteins, respectively, and because some
of the previously tested SIVmac/HIV-2 Vpx variants were
reported to bind VprBP [11,22]. Previous studies have demon-
strated that Vpr binds DDA1-DDB1-VprBP complex via its C-
terminal a-helical region [11,13]. Given the high degree of
sequence identity between Vpx and Vpr proteins, this raised the
possibility that Vpx binds the above complex in a manner similar
to that seen with Vpr [11]. To test this and to develop mutant Vpx
proteins defective for the interaction with DDA1-DDB1-VprBP,
we substituted amino acid residues located in the C-terminal a-
helical region of Vpx that are conserved in Vpr proteins (see
Figure 1B). Mutant Vpx proteins were then transiently expressed
in HEK 293T cells, immunoprecipitated via their FLAG tags, and
immune complexes analyzed by Western blotting. As shown in
Figure 1A, alanine substitution for the conserved glutamine Q76
(Q76A) disrupted Vpx ability to associate with DDA1, VprBP and
DDB1. Also, alanine substitution for the conserved phenylalanine
F80 (F80A) and arginine substitution for histidine 82 (H82R) had
similar effects. Of note, the corresponding mutations in HIV-1
Vpr were previously shown to disrupt the binding to the VprBP-
associated protein complex ([11], data not shown). Finally,
Figure 1. Conserved amino acid residues in Vpx C-terminal region mediate the association with DDA1-DDB1-VprBP complex. (A)
hfa-tagged wild type (lane 2) or mutant (lanes 3–6) Vpx proteins were transiently expressed in HEK 293T cells and precipitated from detergent
extracts with FLAG-M2 affinity resin. DDB1, VprBP, DDA1 and hfa-Vpx were detected in immune complexes (left panel) and cell extracts (right panel)
by immunoblotting and visualized by enhanced chemiluminescence. (B) Amino acid sequences of the C-terminal regions of SIVmac 239 Vpx, SIVmac
239 Vpr, and HIV-1 NL43 Vpr are aligned and amino acid substitutions for the conserved residues in Vpx are indicated. Numbers indicate the positions
of the first amino acid residue shown in each protein sequence. Dots identify amino acid identities and letters specify amino acids in the single-letter
code.
doi:10.1371/journal.ppat.1000059.g001
Vpx Promotes Macrophage Infection via VprBP/DCAF1
PLoS Pathogens | www.plospathogens.org 3 May 2008 | Volume 4 | Issue 5 | e1000059
mutating the conserved glycine G86 and cysteine C87 residues
(GC86NG) did not have a detectable effect. We conclude that Vpx
binds the DDA1-DDB1-VprBP complex via its C-terminal
domain, probably using an interaction surface that is also
conserved in the Vpr protein.
VprBP links Vpx to the Cullin 4 scaffold
The VprBP-DDB1 module was found to bind Cullin 4 and to
participate in a functional Cul4-DDB1[VprBP] E3 ubiquitin ligase
complex [13]. Therefore, we tested whether Vpx can associate
with Cullin 4 and, if so, whether VprBP mediates this association.
hfa-Vpx was transiently expressed together with myc-tagged
Cullin 4A isoform (m-Cul4) and/or myc-tagged VprBP (m-VprBP)
in HEK 293T cells, and anti-FLAG immunoprecipitates were
analyzed for Cullin 4 by immunoblotting. As shown in Figure 2,
VprBP co-expression dramatically elevated the levels of Cullin 4
associated with wild type Vpx, but not with the Vpx(Q76A) variant
that is unable to interact with VprBP and DDB1 subunits of the
E3 complex (compare lane 4 with 2 and 5). We conclude that
VprBP links Vpx to the Cullin 4-based E3 complex.
Notably, we observed that the Vpx-associated Cullin 4 migrated
as a doublet (see lane 4). The slower migrating form of Cullin 4
was much less abundant in immune complexes assembled with
VprBP in the absence of Vpx (lane 9), and co-migrated with the
neddylated form of Cullin 4 shown previously to be induced by
HIV-1 Vpr (see Figure S1, and ref. [13]). As expected, the
upshifted Cullin 4 isoform was not detected in the E3 complex
containing the DDB2 substrate receptor, which is catalytically
repressed in the absence of damaged DNA (lane 7, see ref. [23]).
Notably, in contrast to Vpr, the Vpx-induced modification was
much less pronounced, and did not lead to a robust increase in
catalytic activity of the associated E3 (Figure S1). We conclude
that SIVmac Vpx is a much less potent inducer of Cullin 4
neddylation and E3 catalytic activity, than HIV-1 NL43 Vpr.
Disruption of Vpx binding to VprBP compromises
macrophage transduction by SIVmac
The ability of Vpx to enable infection of primary macrophages
is well documented, yet the immediate downstream mediator(s) of
Vpx remains unknown [1,2,3]. Therefore, experiments were
performed to assess whether the interaction with VprBP and its
associated E3 complex is important for Vpx’s ability to facilitate
macrophage transduction by SIVmac 239. Since this function is
probably mediated by the virion-bound Vpx molecules, our initial
experiments assessed the ability of the mutant Vpx proteins to be
incorporated in SIVmac 239 virions.
VSV-G pseudotyped single cycle SIVmac 239(GFP) viruses
encoding wild type or mutated Vpx variants that do not bind
VprBP, or possessing an inactive vpx coding sequence due to
termination codon substitutions for methione codons M1 and M62
were produced from HEK 293T cells. All viruses contained a
frameshift mutation in the env gene which prevented expression of
a functional Env glycoprotein, and expressed GFP marker protein
from an IRES element positioned immediately downstream of the
nef gene (SIVmac 239(GFP)). A reference panel of virions containing
decreasing amounts of wild type Vpx were also produced from
HEK 293T cells transiently co-expressing SIVmac 239(GFP)
proviral construct possessing wild type vpx gene mixed with an
isogenic construct containing the M1- and M62- mutated vpx, at
1:3, 1:7, or 1:15 ratio. Virions were partially purified and
concentrated by pelleting through 20% sucrose cushion and then
analyzed by immunobloting for p27 Capsid and for Vpx. As
shown in Figure 3A, the Q76A and F80A substitutions had only
minor effects on the abilities of the mutant proteins to be
incorporated into the virions (compare lanes 5 and 6 with 1–4).
The H82R substituted Vpx was incorporated into viral particles
very poorly (data not shown), and therefore was not studied
further.
Next we measured the abilities of the VSV-G pseudotyped
single cycle virions to transduce human monocyte derived
adherent macrophages. Monocytes obtained from human periph-
eral blood mononuclear cells (PBMC) by negative selection for
CD3, CD7, CD16, CD19, CD56, CD123 and Glycophorin were
differentiated into macrophages in the presence M-CSF. Macro-
phage cultures were then infected with normalized virion
preparations and transduction efficiencies of the wild type and
mutant viruses were quantified by flow cytometric analysis of GFP
expression in the infected cell populations. As controls, CD4+ T
lymphocytes purified from PBMC by positive selection for CD4
and activated by phytohemagglutinin in the presence of IL-2, and
Jurkat T cells, were also infected and analyzed in parallel. As
shown in Figure 3B, panels 2–6, wild type Vpx stimulated
macrophage transduction by up to 100-fold, in a dose-dependent
manner (5.1% vs 0.06% GFP-positive cells). Significantly,
Vpx(Q76A), or Vpx(F80A), substituted Vpx failed to support
macrophage infection (panels 7 and 8), even though the mutant
Vpx molecules were efficiently incorporated into the virions. In
contrast, all viruses displayed similar infectivities to primary CD4+
T lymphocytes and Jurkat T cells (panels 9–16 and 17–24),
indicating that Vpx is not required for transduction of primary T
cells and established T cell lines, consistent with previous
observations [2]. Thus, the Q76A and F80A changes link SIVmac
Vpx ability to enhance macrophage transduction to its interaction
with VprBP and its associated E3 ubiquitin ligase complex.
Figure 2. VprBP links Vpx to Cullin 4. myc-tagged Cullin 4A (m-
Cul4) was coexpressed with FLAG- (f-) or myc- (m-) tagged Vpx, VprBP,
DDB2 in HEK 293T cells, as indicated. Protein complexes were
immunoprecipitated via their FLAG-tagged f-Vpx, f-VprBP, or f-DDB2
subunit, and resolved by SDS-PAGE. f- and m-tagged polypeptides were
detected in detergent extracts (extr) and immune precipitates (IP) by
immunoblotting with anti-FLAG or anti-myc epitope antibodies,
respectively. Asterisk (*) indicated a background band that corresponds
to the heavy chain of the anti-FLAG IgG.
doi:10.1371/journal.ppat.1000059.g002
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HIV-2 Vpx also uses VprBP/DCAF1 to enable macrophage
infection
Vpx proteins encoded by HIV-2 viruses also enhance
transduction of monocyte-derived cells, but a previous report
suggested that they may be unable to bind VprBP [22,24]. This in
turn raised a question whether HIV-2 Vpx uses a VprBP-
independent mechanism to enable macrophage infection. To
address this issue we asked whether Vpx variant encoded by HIV-
2 Rod proviral clone binds VprBP. We chose this particular Vpx
variant because it is required for the ability of HIV-2 Rod to
transduce primary macrophages and, therefore, is functional [24].
Of note, it is evident from phylogenetic analyses that both the Rod
Vpx and SIVmac 239 Vpx are representative of two major groups
of HIV-2 Vpx variants (see Figure S2). As shown in Figure 4A,
wild type, but not Q76A-substituted, Rod Vpx protein readily
bound VprBP in a transient expression assay in HEK 293T cells
(compare lanes 1 and 2). Next we assessed the abilities of both
proteins to enhance macrophage transduction by a single cycle
SIVmac 239(GFP) reporter virus. We found that only wild type Rod
Vpx rescued the infectivity of single cycle SIVmac 293(GFP)
reporter virions that were devoid of SIVmac Vpx, even though
both the wild type and Q76A substituted Rod Vpx variants were
Figure 3. Q76A and F80A substitutions in Vpx disrupt ability of SIVmac 239 to transduce macrophages. (A) Q76A and F80A substituted
Vpx are efficiently incorporated into SIVmac virions. Reference VSV-G pseudotyped single cycle SIVmac 239(GFP) virions containing decreasing
amounts of wild type Vpx were produced from HEK 293T cells transiently transfected with the SIVmac 239(GFP) proviral clone containing wild type vpx
gene alone (lane 1), or co-transfected with isogenic proviral clones containing wild type or inactivated vpx genes, and mixed at 1:3 (0.25, lane 2), 1:7
(0.12, lane 3) or 1:15 (0.06, lane 4) ratios. Partially purified virions were immunoblotted for Vpx (Vpx) and p27 Capsid (CA p27). (B) Human monocyte-
derived adherent macrophages (MF, panels 1–8), primary CD4+ T lymphocytes activated with PHA and IL-2 (CD4+, panels 9–16), and Jurkat T cells (JK,
panels 17–24) were infected with normalized amounts of VSV-G pseudotyped single cycle SIVmac 239(GFP) virions containing various amounts of wild
type (panels 2–6, 10–14, 18–22), or Q76A (panels 7, 15, 23) and F80A (panels 8, 16, 24) substituted Vpx proteins, or mock infected (panels 1, 9 and 17).
Cells were harvested 4 days (MF), or 2 days (CD4+ and JK), following infection and GFP expression in the transduced populations was analyzed by
flow cytometry. Bivariant plots of GFP expression (abscissa) versus forward scatter (ordinate) are shown. Percent fractions of GFP-positive cells
(boxed) are indicated. Of note, SIVmac 239(GFP) containing wild type Vpx transduced between 5% and 60% of macrophages and Vpx enhanced
transduction between 20-fold and 100-fold in 6 independent experiments, which probably reflects the donor-dependent variability of macrophage
populations used.
doi:10.1371/journal.ppat.1000059.g003
Vpx Promotes Macrophage Infection via VprBP/DCAF1
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Figure 4. HIV-2 Rod Vpx facilitates macrophage transduction through its interaction with VprBP. (A) HIV-2 Rod Vpx binds VprBP/DCAF1.
hfa-tagged wild type (lanes 1 and 4) or Q76A substituted (lane 2 and 5) HIV-2 Rod Vpx proteins were transiently expressed in HEK 293T cells and
precipitated from detergent extracts with FLAG-M2 affinity resin. VprBP and hfa-Vpx were detected in immune complexes (left panel) and cell extracts
(right panel) by immunoblotting and visualized by enhanced chemiluminescence. (B) Wild type and Q76A substituted HIV-2 Rod Vpx proteins are
incorporated into SIVmac virions. VSV-G pseudotyped single cycle SIVmac 239(GFP) virions were produced from HEK 293T cells transiently
coexpressing wild type (lane 2) or Q76A mutated (lane 3) Rod Vpx, SIVmac 239(GFP) proviral clone with disrupted vpx and env genes, and VSV-G.
Virions were partially purified and analyzed for Vpx and p27 Capsid by Western blotting. (C) Human monocyte-derived macrophages (MF, panels 1–
4), and Jurkat T cells (JK, panels 5–8) were infected with normalized amounts of viruses characterized in (B) above, or mock infected (panels 1 and 5),
and GFP positive cells were determined after 4 days (MF), or 2 days (JK), by flow cytometry. Percent fractions of GFP-positive cells (boxed) are
indicated.
doi:10.1371/journal.ppat.1000059.g004
Vpx Promotes Macrophage Infection via VprBP/DCAF1
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incorporated into the virions to similar extents (Figure 4B and 4C).
We conclude that the interaction with VprBP is a conserved
function of SIVmac and HIV-2 Vpx proteins, and that both use
VprBP to enable macrophage infection.
Vpx uses VprBP to support reverse transcription of
SIVmac in macrophages
Vpx was reported to be essential for efficient reverse
transcription and/or nuclear import of lentiviral genomes in
monocyte-derived cells [3,8]. Hence we examined the effect of
Q76A and F80A substitutions in Vpx on reverse transcription
(RT) of the incoming SIVmac genomes by real-time quantitative
fluorescent PCR. Macrophages were transduced with a reference
panel of VSV-G pseudotyped single cycle SIVmac 239(GFP) virions
containing decreasing amounts of wild type Vpx, or Vpx(Q76A) and
Vpx(F80A) variants, characterized in Figure 3A. DNA was isolated
from the transduced cells 18 hours and 72 hours later and RT
intermediates were quantified by real time PCR with four sets of
primers shown in Figure 5A. The primers were designed to
amplify strong-stop DNA (early), RT products synthesized
immediately following minus strand transfer (U3), or a region of
the gag gene located approximately 8000 nucleotides distal from
U3 (gag), as well as late RT products synthesized following
successful plus strand transfer (late). As shown in Figure 5B, these
analyses revealed that reverse transcription was defective following
infection with virions lacking, or containing suboptimal amounts of
Vpx. First, the steady state levels of the early strong-stop RTs were
approximately 10-fold lower in the absence of Vpx and the
magnitude of the decrease was inversely correlated with the Vpx
virion content. Second, the levels of U3, gag and late RTs were
progressively lower upon infection with Vpx-deficient virions
(approx 100-fold, 300-fold and 1000-fold, respectively) at the
18 hour time point. These differences were less pronounced at the
72 hour time point. Importantly, Vpx was not required for
efficient reverse transcription following infection of Jurkat T cells.
Together, these observations indicate that Vpx is required for
events that lead to an efficient initiation and progression of reverse
transcription of SIVmac genome in macrophages.
Figure 5. Reverse transcription of SIVmac 239(GFP) virions comprising Vpx(Q76A) and Vpx(F80A) in macrophages is compromised. (A)
Location of reverse transcription intermediates used to gauge the progression of reverse transcription of SIVmac 239(GFP) genome. Regions amplified
by ‘‘early’’, ‘‘U3, ‘‘gag’’ and ‘‘late’’ sets of oligonucleotide primers are represented by grey boxes. The thin line represents viral RNA and the locations of
the R, U5, primer binding site (PBS), packaging signal (Y), polypurine tract (PPT) and U3 regions are indicated. The thick arrows represent viral cDNA.
(B) Steady state levels of reverse transcription intermediates following infection with VSV-G pseudotyped single cycle SIVmac 239(GFP) virions deficient
in Vpx. Macrophages and Jurkat T cells were infected with the reference set of SIVmac 239(GFP) virions containing various amounts of wild type Vpx,
characterized in Figure 3. DNA was prepared from the infected cells 18 hour or 72 hours following infection and 50 ng aliquots were analyzed in
duplicate by real time PCR with oligonucleotide primers that recognize ‘‘early’’(E), ‘‘U3’’(3), ‘‘gag’’(G) and ‘‘late’’(L) reverse transcription products, as
indicated below the histograms. The amounts of reverse transcription products were calculated by comparison to standard curves generated with
serially diluted SIVmac 239 proviral DNA and are shown in red and blue for the 18-hour and 72-hour timepoint, respectively. The variances between
duplicate data points were less than 4%. (C) Q76A and F80A substitutions disrupt Vpx function in macrophages. Macrophages were not infected (u)
or infected with single cycle SIVmac 239(GFP) virions containing Q76A (76) or F80A (80) substituted, wild type (V+), or no Vpx (V2), characterized in
Figure 3A, and reverse transcription was analyzed with ‘‘early’’ and ‘‘late’’ primers as described above.
doi:10.1371/journal.ppat.1000059.g005
Vpx Promotes Macrophage Infection via VprBP/DCAF1
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Next we tested the effects of Q76A and F80A substitutions in
SIVmac Vpx for its ability to enable efficient reverse transcription
of the SIVmac genome in macrophages. As shown in Figure 5C,
both Vpx variants conferred a Vpx-deficient virion phenotype.
Since Q76A and F80A each disrupts Vpx binding to VprBP, these
findings link the interaction with VprBP to Vpx ability to facilitate
reverse transcription of lentiviral genome in macrophages.
VprBP mediates macrophage transduction by SIVmac
To obtain further insight into the role of VprBP, we knocked
down its expression in macrophages by RNA interference (RNAi,
[25]). As illustrated in Figure 6A, a pool of small interfering RNAs
(siRNA) targeting VprBP, but not the control non-targeting
siRNAs, severely diminished VprBP expression (compare lane 3
with 1 and 2). Two days following initiation of RNAi macrophages
were infected with VSV-G pseudotyped single cycle SIVmac
239(GFP) reporter virus and the transduction efficiency was assessed
3 days later. Flow cytometry analysis of GFP expression revealed
that nontargeting siRNA decreased transduction efficiencies by
only approximately 30% and the magnitude of this effect was
constant over a wide range of siRNA concentrations (Figure 6B,
compare panels 4 and 6 with 2). A similar result was observed with
another non-targeting siRNA pool (data not shown). These
observations indicate that non-specific engagement of RNAi
machinery had only a minor negative effect on macrophage
transduction by SIVmac 239. In contrast, RNAi to VprBP
decreased transduction efficiency by approximately 10-fold at a
lower dose, and 30-fold at a higher dose of the targeting siRNA
(compare panel 3 with 4 and 5 with 6). These experiments were
repeated 4 times and we consistently observed a decrease in
transduction efficiency following RNAi to VprBP, ranging
between 6-fold and .100-fold. To further exclude the possibility
that the observed resistance of VprBP-depleted macrophages to
SIVmac infection is caused by the off target effects of the siRNA
pool targeting VprBP, additional experiments were performed
using individual VprBP-specific siRNAs (Figure S3). We observed
good correlation between the abilities of the four siRNAs to knock
down VprBP expression and to disrupt macrophage transduction
by SIVmac 239(GFP) reporter virus. Of note, VprBP-depletion in
U2OS cells did not compromise transduction of these cells by
Figure 6. VprBP is important for the ability of SIVmac 239 to transduce macrophages. (A) Depletion of VprBP levels in macrophages by
RNAi. Detergent extracts prepared from macrophages (lane 1) transfected with a control non-targeting siRNA (lane 2, scr) or siRNA pool targeting
human VprBP (lane 3, VBP) four days after initiation of RNAi were analyzed by immunoblotting with rabbit anti-VprBP IgG, or with an antibody to the
a-subunit of the AP-2 clathrin adaptor complex (a-ad), to control for equal loading. (B) and (C) VprBP-depleted macrophages resist SIVmac 239
infection. Macrophages transfected with the indicated amounts of VprBP-targeting (panels 3 and 5) or non-targeting (panels 4 and 6) siRNA pools
and nontransfected macrophages (panel 2) were infected with VSV-G pseudotyped SIVmac 239(GFP) virus two days after initiation of RNAi. Flow
cytometric analysis of GFP expression (B) and real time PCR quantification of gag DNA (C) in the transduced populations were performed 3 days later.
doi:10.1371/journal.ppat.1000059.g006
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SIVmac 239(GFP) reporter virus regardless of the presence or
absence of Vpx (Figure S4). Together these data indicate that
VprBP is required for efficient macrophage transduction by
SIVmac.
If VprBP indeed facilitates macrophage transduction through
the interaction with Vpx, we expected the arrest of SIVmac
replication in the absence of VprBP and that in the absence of Vpx
to be similar in nature. To test this prediction we examined the
steady state levels of SIVmac 239(GFP) late reverse transcription
products 72 hours post infection of VprBP-depleted and control
macrophage populations, by real time PCR. As expected, the
levels of late reverse transcripts were approximately 100-fold lower
in VprBP-depleted versus non-targeting siRNA treated, or
untreated macrophages (Figure 6C, compare VprBP to scr, or
none). Together our data indicate that VprBP has an important
role in macrophage transduction by SIVmac and that this function
requires Vpx.
Discussion
Vpx enables efficient transduction of monocyte-derived cells,
such as macrophages and DC’s by SIVsm/mac and HIV-2
viruses; however the mechanism that mediates this effect has not
been identified. Our findings link this Vpx function to its ability to
interact with components of the ubiquitin proteasome system and
identify a ternary protein complex - comprising DDA1, DDB1 and
VprBP/DCAF1, a putative substrate receptor for Cullin 4-based
E3 ubiquitin ligase - as the immediate downstream effector that
Vpx uses to promote macrophage transduction. Importantly, the
DDB1-VprBP/DCAF1 module was previously shown to partici-
pate in a functional Cullin 4 E3 ubiquitin ligase complex [13].
Together, these findings support a model in which Vpx usurps the
Cullin 4 E3 ubiquitin ligase utilizing the VprBP/DCAF1 to
overcome a block to lentivirus replication upon its entry into
monocyte-derived cells.
Our data indicate that Vpx acts early following virion entry into
macrophages to allow efficient initiation as well as completion of
reverse transcription of the incoming SIVmac RNA genomes. This
can be clearly seen from a .10-fold decrease in steady state levels
of early reverse transcription products and 103-fold decrease in late
reverse transcripts upon challenge with Vpx-deficient virions.
These phenotypes could result from defects in virion uncoating
and/or in its transit into a permissive cytoplasmic compartment.
A similar, albeit less dramatic, loss of vpx function phenotypes
were previously reported for other SIVsm/mac viral isolates and/
or vpx alleles upon infection of monocyte-derived DCs [8]. The
finding that Vpx is required for efficient reverse transcription in
macrophages was somewhat surprising, because it has been
thought that this factor acts at a later stage in the replication
cycle by enabling the import of the fully reverse transcribed
preintegration complex into the nucleus [3]. Our findings, taken
together with these previous observations, indicate that SIVmac
replication is restricted by the same mechanism in DCs and in
macrophages. Thus, it is important to refocus future studies
towards post entry events that precede reverse transcription in
these monocyte derived cells.
The phenotype of Vpx-deficient virions is reminiscent of that
resulting from a block to retrovirus replication imposed by
tripartite motif protein 5a (TRIM5a) restriction factors.
TRIM5a is a E3 ubiquitin ligase that inactivates the incoming
virions, probably by deregulating their uncoating so rapidly
that the late reverse transcripts fail to accumulate [26,27,28].
Also, the observation that proteasome inhibitors partially rescue
reverse transcription of Vpx-deficient viruses in DCs is
consistent with the idea that SIVmac virions may be targeted
by a TRIM5a-like restriction, or by another E3 ubiquitin
ligase in monocyte-derived cells [8]. Whereas these observa-
tions raise the possibility that Vpx could act by counteracting
TRIM5a, we note that this is not likely, because TRIM5a is
expressed in Jurkat T cells [29], which we found not to restrict
Vpx-deficient SIVmac virions.
How does Vpx facilitate reverse transcription in macrophages
via its interaction with VprBP? As mentioned above, a recent
study suggested that the replication of SIVmac cells could be
restricted, at least in part, by an as yet unidentified E3 ubiquitin
ligase [8]. We initially considered that VprBP-linked Cullin 4 E3
complex could be that enzyme and that Vpx counters the
restriction by inhibiting its activity. However, our data from RNAi
experiments revealed that VprBP is not required for the restriction
to occur and, therefore, do not support this possibility.
Furthermore, the incoming virions probably contain at most only
several hundred Vpx molecules, similar to Vpr, which also is
virion recruited through its interaction with Gag p6 [6,30,31].
Therefore, it is difficult to envision that the limited amounts of
virion-bound Vpx would be able to saturate and inhibit the
cellular pool of VprBP-associated Cullin 4 E3 complexes, even by
a noncompetitive mechanism.
Instead of blocking SIVmac replication, our evidence
indicates that VprBP is required for Vpx to overcome the
block, implying that Vpx uses VprBP-associated E3 to enable
reverse transcription in macrophages. Notably, the same
VprBP-associated ubiquitin ligase was shown previously to be
targeted by a Vpx paralogue, Vpr, which stimulates the intrinsic
catalytic activity ofthis E3 [13]. The findings that both Vpx and
Vpr interact with VprBP in a similar manner via their C-
terminal regions, and that both interactions lead to post-
translational modification of their associated Cullin 4 subunits
suggest that Vpx also usurps the VprBP-associated E3, probably
to inactivate a cellular factor that inhibits lentivirus replication
in macrophages and DC’s. Indeed, viral accessory proteins are
known to utilize E3 ubiquitin ligases to direct ubiquitination and
proteasomal degradation of cellular proteins that mediate innate
immunity to viral infection [32].
Both Vpx and Vpr bind VprBP through similar molecular
interactions, yet the functional outcomes are different. Vpr uses
VprBP-associated E3 to activate DNA damage checkpoint
controlled by the Ataxia-telangiectasia and Rad3-related (ATR)
kinase, while Vpx does not have this function and, instead, enables
efficient reverse transcription of SIVmac genome in monocyte-
derived cells [33]. These different outcomes likely reflect that Vpr
and Vpx recruit different sets of substrates for ubiquitination by
the same E3 enzyme [34,35], and that they affect differently the
activities of their associated Cullin 4 E3s (see Figure S1). It will be
important in the future to identify cellular proteins whose
ubiquitination is altered by Vpx and Vpr in order to advance
the understanding of these important virulence factors.
In summary, our findings provide novel insights into the
mechanism by which Vpx enables macrophage infection, as they
link this function to Vpx interaction with VprBP and its associated
Cullin 4 E3 ubiquitin ligase complex. Further studies of how Vpx
manipulates protein ubiquitination through its interaction with
VprBP should lead to detailed understanding of the biochemical
mechanism that limit replication of primate lentiviruses in
monocyte-derived cells, and how it is countered by viruses of the
HIV-2/SIVmac/sm lineages. This knowledge in turn will likely
lead to the conception of new strategies aimed to prevent the virus
from establishing reservoirs in these cells.
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Materials and Methods
Expression plasmids
pCG expression vectors expressing epitope tagged VprBP/
DCAF1, DDB1, DDA1, Cullin 4A, and Vpr proteins of HIV-1
NL43 and SIVmac 239 viruses were described previously [13].
SIVmac 239 Vpx was tagged with hfa- triple epitope tag and
subcloned into BABE(puro) and pCG vectors [13]. HIV-2 Rod vpx
gene was amplified by PCR from Rod proviral clone [24] kindly
provided by Michael Emerman (Fred Hutchinson Cancer
Research Center, Seatte). Mutations were introduced using
QuikChange XL II kit (Stratagene, La Jolla, CA, United States)
and confirmed by DNA sequencing.
Transient transfections of HEK 293T cells,
immunoprecipitations, and immunoblotting
HEK 293T cells were transfected by calcium phosphate co-
precipitation method. Detergent extracts and anti-FLAG im-
mune complexes were analyzed by immunobltting as described
previously [36]. FLAG-, HA- and myc- epitope tagged proteins
were detected with anti-FLAG M2 (Sigma-Aldrich, St. Louis,
MO, United States), 12CA5, and 9E10 monoclonal antibodies
(mAb), respectively. The following antibodies were also used:
anti-DDB1 (37-6200) from Zymed (Invitrogen, Carlsbad, CA,
United States), anti-a-adaptin (AC1-M11) from Alexis Corp (San
Diego, CA, United States), anti-Gag SIVmac 251 (13-112-100)
from Advanced Biotechnologies Inc. (Columbia, MD, United
States) and anti-Vpx 6D2.6 Vpx hybridoma supernatant. DDA1
and VprBP were detected with rabbit sera raised to recombinant
proteins [13].
Immunoaffinity purification of epitope-tagged proteins
and MudPIT analysis
SIVmac 239 Vpx and its associated proteins were purified from
U937 cells stably expressing hfa-tagged Vpx, or HEK 293T cells
transiently expressing hfa-Vpx by two sequential immunoprecip-
itations via FLAG and HA epitope tags, each followed by
competitive elution with the appropriate peptide epitope. MudPIT
analysis was performed as described previously [13]. Tandem
mass (MS/MS) spectra were interpreted using SEQUEST [37]
against a database of 82242 sequences, consisting of hfa-tagged
SIVmac Vpx, usual contaminants, and 40873 human proteins, as
well as, to estimate false discovery rates, randomized amino acid
sequences derived from each non-redundant protein entry.
Peptide hits from multiple runs were compared using CON-
TRAST [38].
SIVmac 239 proviral clones and viruses
Vpx and Vpr mutations were introduced into a single cycle
SIVmac 239(GFP) reporter proviral clone containing a frameshift
mutation in the env gene constructed by filling in a unique ClaI site
[39]. A proviral clone deficient for vpx was constructed by
substituting methionine and serine codons at positions 1 and 2 in
vpx with threonine and termination codons, respectively, such as
not to alter the overlapping vif gene. The second consecutive
methionine codon (M62) in vpx was also changed to a termination
codon to prevent the possibility that a truncated C-terminal
fragment of Vpx protein will be expressed. Mutagenesis was
performed with QuikChange XLII kit (Stratagene) using 1.3 kb
PacI-SphI fragment of SIVmac 239(GFP) provirus [39] that
comprises vif and vpx open reading frames, subcloned into pCR
2.1 vector, as a template. All mutations were confirmed by DNA
sequencing and reintroduced into SIVmac 239(GFP) proviral clones
containing a frameshift mutation in env, by exchanging the 1.3 kb
PacI-Sph1 restriction fragment. VSV-G pseudotyped single cycle
viruses were produced from HEK 293T cells transiently
transfected with proviral clones and a VSV-G expression plasmid.
In some experiments vpx-defective SIV were complemented in
trans with wild-type or mutant Vpx proteins expressed from
cotransfected pCG vectors. Culture medium was harvested
24 hours after transfection, cell debris removed by centrifugation
at 7,000 rpm for 10 minutes and virus containing supernatants
were then treated with DNAse I (Roche) for 60 minutes at 30uC.
Viral particles were partially purified and concentrated by
pelleting through 20% sucrose in 10 mM Tris-HCl [pH 7.4],
100 mM NaCl, 1 mM EDTA cushion at 27,000 rpm for 3 hours.
Virion preparations were normalized based on reverse transcrip-
tase assays and/or infectivity to Jurkat T cells, and stored at
270uC.
Preparation of macrophage and CD4+ T cells, infections
and flow cytometry analysis
Monocytes obtained from human PBMCs by negative selection
for CD3, CD7, CD16, CD19, CD56, CD123 and Glycophorin
using Monocyte Isolation Kit II (Miltenyi Biotec Inc., Auburn,
CA, United States), were plated in 24 well plates at 4–76105 cells/
well and differentiated into macrophages by culturing in DMEM
supplemented with 10% fetal bovine serum (FBS), Macrophage-
Colony Stimulating Factor (M-CSF, 50 ng/ml, R&D Systems,
Minneapolis, MN, United States) for 6 days. Cells were fed every
alternate day by replacing one half of the cell culture medium with
fresh medium. Purity of CD14+ cells obtained by negative
selection with the Monocyte Isolation Kit II from Miltenyi usually
ranged between 95% and 99% while the final purity of the
adherent macrophage population was typically greater than
99.9%. RNA interference was initiated at day 6 and followed by
infections with SIVmac on day 8. Cells were harvested for QPCR
analysis of reverse transcription products 18 hours to 72 hours
post infection. Flow cytometry analysis of GFP expression was
performed 4 days post infection. Macrophages were detached
from wells by trypsin treatment, resuspended in 1% paraformal-
dehyde and GFP expression analyzed by flow cytometry. CD4+ T
cells were purified from PBMC using CD4+ T cell isolation kit
(Miltenyi Biotec) and stocks were frozen in 107 cell aliquots. Stocks
were plated in 5 ml of RPMI 1640 supplemented with 10% FBS,
2 mM glutamine, 10 mM HEPES, pH = 7.4, 50 mM b-mercap-
toethanol, and containing phytohemagglutinin (PHA, 10 mg/ml)
and recombinant human IL-2 (10 u/ml, Roche) in single wells of a
6 well plate. After 48 hours cultures were diluted into the same
medium but without PHA and 56105 cell aliquots were infected
in the total volume of 2 ml in wells of a 24 well plate. Expression of
GFP marker protein was quantified 48 hours post infection by
flow cytometry.
Real time PCR
SIV reverse transcription products were quantified by real time
PCR on ABI PRISM 7700 SDS. A typical reaction contained
50 ng of DNA isolated with DNAeasy Kit (Qiagen, Valencia, CA,
United States) from infected or control cells and SYBR Green
PCR master mix in a total volume of 25 ml (Applied Biosystems,
Foster City, CA, United States). Early reverse transcription
products were amplified with ERT.2.s (59-CTTGCTTGC-
TTAAAGCCCTCTT-39) and S.ERT.as (59-CAGGGTCTTCT-
TATTATTGAGTACC-39) primers, U3 with U3.SIV.s (59-
ATCATACCAGATTGGCAGGATT-39) and U3.SIV.as (59-
GAAGTTTGAGCTGGATGCATTA-39), gag with SIV.GAG.s
(59-ATTAGTGCCAACAGGCTCAGA-39) and SIV.GAG.as (59-
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GCATAGTTTCTGTTGTTCCTGTTT-39), late with SIV.1
(59-AGCTAGTGTGTGTTCCCATCTC-39) and SIV.3 (59-
TACTCAGGAGTCTCTCACTCTCCT-39).
Serial dilutions of known amounts of a plasmid containing
SIVmac293 provirus, served as a copy number standard to
generate standard curves.
RNA interference
Macrophages cultured in 24 well plates (Becton & Dickinson, San
Jose, CA, United States) were fed with antibiotic free 10% serum
containing DMEM 24 hrs before transfections. Cells were trans-
fected with 1–200 pmol aliquots of a control nontargeting pool of
siRNA (D-001206-14-05, Dharmacon, Lafayette, CO, United
States) or ON-TARGET plus SMARTpool siRNA targeting
human VprBP (L-021119-01), or individual VprBP-specific siRNAs
(VprBP1 sense: GAUGGCGGAUGCUUUGAUAUU, antisense:
UAUCAAAGCAUCCGCCAUCUU; VprBP2 sense: GGAGG-
GAAUUGUCGAGAAUUU, antisense: AUUCUCGA-
CAAUUCCCUCCUU; VprBP3 sense: ACACAGAGUAU-
CUUAGAGAUU, antisense: UCUCUAAGAUACUCUGUGA-
UU; VprBP10 sense: CCACAGAAUUUGUUGCGCAUU, anti-
sense: UGCGCAACAAAUUCUGUGGUU) using Lipofectamine
2000 (Invitrogen) according to manufacturer’s instructions. Briefly,
siRNA stocks were prepared in phosphate buffered saline (PBS).
Liposomes were formed using 4 ml of Lipofectamine 2000 per well,
as recommended by manufacturer (Invitrogen). 4–6 hours post
transfection culture medium was replaced with fresh antibiotic-free
DMEM supplemented with 10% FBS. U2OS cells were plated at
56104/well of 12 well plate in 1 ml of DMEM supplemented with
10% FBS and 2 mM glutamine in the absence of antibiotics
24 hours before initiation of RNAi. Cells were transfected with
lipofectamine 2000 (4 ml/well) containing indicated amounts of
siRNA duplexes in 0.5 ml of medium, and the medium was
replaced with 1 ml of fresh medium 5 hours later. 48 hours
following initiation of RNAi cells were harvested for immunoblot
analysis of VprBP expression, or infected with SIVmac or HIV-1
derived vectors. Transduction efficiencies were quantified by flow
cytometric analysis of GFP expresssion.
Supporting Information
Figure S1 Characterization of Vpx-associated Cullin 4 E3
complex. (A) SIVmac Vpx and HIV-1 NL43 Vpr induce post-
translational modification of Cullin 4. Myc-tagged Cullin 4A (m-
Cul4) was expressed alone (lane 1), or together with FLAG-tagged
SIVmac 239 Vpx (f-Vpx, lane 2), or HIV-1 NL43 Vpr (f-Vpr(H),
lane 3) in HEK 293T cells. Ectopically expressed Cullin 4A and
Vpr/Vpx were detected in detergent extracts with anti-myc- or
anti-FLAG- epitope antibodies, respectively. (B) In vitro intrinsic
ubiquitin ligase activities of SIVmac Vpx and HIV-1 NL43 Vpr -
associated E3 complexes. Cul4-DDB1[VprBP] E3 complexes were
assembled in the absence (lanes 1, 2) or in the presence (lanes 3, 4)
of Vpx, or Vpr (lanels 5, 6), in HEK 293T cells and puri-
fied by immunoprecipitation via their FLAG-tagged VprBP
subunits (13). Protein complexes were incubated with E1 and
ubiquitin in the presence, or absence, of E2 as indicated. Cullin 4A
and its ubiquitinated forms were detected by immunoblotting for
Cullin 4.
Found at: doi:10.1371/journal.ppat.1000059.s001 (0.38 MB TIF)
Figure S2 Phylogenetic relationship between SIVmac 239 and
HIV-2 Vpx protein variants. (A) Unrooted phylogenetic tree was
constructed using Vpx amino acid sequences encoded by fully
sequenced HIV-2 viruses found in Genbank database in
December 2007 (identified by their GenBank accession numbers),
and CLUSTALW and Phylip software. SIVmac 239 Vpx was also
included in the analysis. To more accurately reflect Vpx diversity,
closely related sequences such as those of multiple virus isolates
from the same individual were considered redundant and excluded
from the analysis. SIVmac 239 and HIV-2 Rod Vpx variants are
highlighed. (B) Multiple sequence alignment of HIV-2 Vpx amino
acid sequences. Consensus HIV-2 Vpx amino acid sequence is
shown in the top line. SIVmac 239 Vpx amino acid sequence is
also included for comparison. Amino acid residues corresponding
to those found to be critical for the interaction of SIVmac 239 Vpx
with DDA1-DDB2-VprBP complex (Q76, F80, H82) are boxed. (.)
indicate amino acid identity and (-) represent gaps introduced for
optimal sequence alignment.
Found at: doi:10.1371/journal.ppat.1000059.s002 (0.36 MB TIF)
Figure S3 siRNA mediated inhibition of macrophage transduc-
tion by SIVmac 239 correlates with depletion of VprBP expression
levels. Experiments were performed to correlate the ability of
siRNA duplexes to knock-down VprBP expresion and to disrupt
macrophage transduction by SIVmac 239. (A) RNAi was
performed in U2OS cells with four individual siRNAs to VprBP:
VprBP1, VprBP2, VprBP3 and VprBP10 and with a nontargeting
siRNA (scr) as a negative control, at 0.5 pmol/well in 12 well
plates. VprBP expression levels were assessed by immunoblotting 2
days after initiation of RNAi. Cell extracts were also probed with
antibody specific for a-adaptin subunit of the AP-2 clathrin
adaptor complex to confirm equal loading. HEK 293T cells
transiently overexpressing VprBP were used as a positive control
(lane 8). (B). Macrophages were infected with VSV-G pseudotyped
single round SIVmac 239(GFP) reporter viruses two days following
the initiation of RNAi, and GFP marker expression was analyzed 4
days later by flow cytometry.
Found at: doi:10.1371/journal.ppat.1000059.s003 (0.60 MB TIF)
Figure S4 VprBP/DCAF1 is not important for the ability of
SIVmac 239 to transduce U2OS cells. RNAi to VprBP was
performed in U2OS cells with 0.5, 2.5 and 10 pmol of VprBP10
siRNA, or 2.5 and 10 pmol of nontargeting control siRNA/well in
12 well plates. 2 days after initiation of RNAi cells were (A)
harvested for immunoblot analysis of VprBP expression levels, or
(B) infected with VSV-G pseudotyped SIVmac 239(GFP) reporter
viruses possessing wild type Vpx (Vpx+), or not (Vpx2). GFP-
positive cells was quantified by flow cytometry two days later.
Transduction efficiencies were normalized to those seen with
control U2OS cells that were not subjected to RNAi. Labels at the
bottom of the histogram indicate data from U2OS cell populations
that have not been subjected to RNAi (n), were treated with
10 pmol of nontargeting siRNA (c), or with 0.5 (1), 2.5 (2) and 10
(3) pmol of VprBP10 siRNA/well in 12 well plates.
Found at: doi:10.1371/journal.ppat.1000059.s004 (0.45 MB TIF)
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